Macular Edema clinical trials at UCSD
1 in progress, 0 open to eligible people

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME). The global enrollment phase has closed, but participants are still being recruited only at sites in China.